Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2422613 | 0.83 | ESR1 (0.57) | KMT2AFFAR2ESR1ESR2 | |
| SCHEMBL22838087 | 0.83 | KMT2A (0.55) | KMT2ACYP1A2ALOX5ALDH1A1SMN1; SMN2 | |
| SCHEMBL8984177 | 0.83 | KMT2A (0.55) | KMT2AALOX5FFAR2ESR1ESR2 | |
| SCHEMBL5516974 | 0.83 | ESR1 (0.57) | KMT2AFFAR2ESR1ESR2 | |
| SCHEMBL17084124 | 0.83 | KMT2A (0.55) | KMT2AALOX5FFAR2ESR1ESR2 | |
| SCHEMBL5510967 | 0.83 | ESR1 (0.57) | KMT2AFFAR2ESR1ESR2 | |
| SCHEMBL7171 | 0.82 | MAPT (0.45) | KMT2ACYP1A2ALOX5ALDH1A1SMN1; SMN2 | |
| SCHEMBL9908240 | 0.81 | KMT2A (0.53) | KMT2AALDH1A1FFAR2ESR1ESR2 | |
| SCHEMBL2423106 | 0.81 | FFAR2 (0.64) | KMT2AALDH1A1FFAR2 | |
| SCHEMBL5519250 | 0.81 | KMT2A (0.53) | KMT2AALDH1A1FFAR2ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758059-B1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME (US) | 2018-10-24 | — | — | EP | disclosed |
| US-9079930-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-07-14 | — | — | US | disclosed |
| US-9079930-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20140349972-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140349972-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP (US) | 2014-11-27 | — | — | US | disclosed |
| EP-2758059-A1 | SUBSTITUTED PYRIMIDINES | Merck Sharp & Dohme Corp. (US) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013043624-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013043624-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013040790-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-7939672-B2 | Phenylacetate derivatives or pharmaceutically acceptable salts thereof, preparation method thereof and composition for prevention or treatment of diseases induced by activation of T-type calcium ion channel containing the same as an active ingredient | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-05-10 | — | — | US | disclosed |
| US-20100056545-A1 | NOVEL PHENYLACETATE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES INDUCED BY ACTIVATION OF T-TYPE CALCIUM ION CHANNEL CONTAINING THE SAME AS AN ACTIVE INGREDIENT | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140349972-A1 | SUBSTITUTED PYRIMIDINES | HIF1AN, HIF1A, EGLN3 | KMT2A 408/4885CYP1A2 1189/4885ALOX5 1656/4885 |
| US-20100056545-A1 | NOVEL PHENYLACETATE DERIVATIVES OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PREPARATION METHOD THEREOF AND COMPOSITION FOR PREVENTION OR TREATMENT OF DISEASES INDUCED BY ACTIVATION OF T-TYPE CALCIUM ION CHANNEL CONTAINING THE SAME AS AN ACTIVE INGREDIENT | CACNA1A, CACNA1G, CACNA1H | KMT2A 1248/4885CYP1A2 1092/4885ALOX5 1854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.